US generic margins are thin to absorb any import duty hike, the company said. (Source: Laurus Labs/X) Show Quick Read Summary is AI Generated. Newsroom Reviewed

Laurus Labs Ltd. does not anticipate any significant implications of the US tariff of 100% on branded or patented pharmaceutical products, according to a top executive.

"It is too early to comment, as the world needs to understand the process to be followed by the US. However, we don’t see any significant implication of the additional tariff announcements," Satyanarayana Chava, founder and chief executive officer, said in a statement.

The Trump administration will impose a 100% import tariff starting Oct. 1 on branded or patented drugs unless a company has or is building a manufacturing plant in the US. This presents a fres

See Full Page